Axacus Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.00 M
as on 24-10-2024
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.99 Cr
as on 24-10-2024
- Revenue -7.35%
(FY 2023)
- Profit 7.54%
(FY 2023)
- Ebitda 19.01%
(FY 2023)
- Net Worth 34.13%
(FY 2023)
- Total Assets 6.12%
(FY 2023)
About Axacus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.99 Cr.
Mahesh Rathi, Shyamsunder Maheshwari, Bharatkumar Chandak, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24305GJ2019PTC108457
- Company No.
108457
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jun 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Axacus Pharma?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manish Rathi  | Director | 16-Oct-2019 | Current |
| Mahesh Rathi | Director | 16-Oct-2019 | Current |
| Shyamsunder Maheshwari | Director | 03-Jun-2019 | Current |
| Bharatkumar Chandak | Director | 03-Jun-2019 | Current |
| Shankarlal Chandak | Director | 03-Jun-2019 | Current |
| Dilipkumar Maheshvari | Director | 16-Oct-2019 | Current |
Financial Performance of Axacus Pharma.
Axacus Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 7.35% decrease. The company also saw a slight improvement in profitability, with a 7.54% increase in profit. The company's net worth Soared by an impressive increase of 34.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Axacus Pharma?
In 2023, Axacus Pharma had a public holding of 31.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Agile Wellness Private LimitedActive 3 years 5 monthsShyamsunder Maheshwari and Anilkumar Shankarlal are mutual person
- B First Pharma Private LimitedActive 2 years 11 months
Bharatkumar Chandak and Dilipkumar Maheshvari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 31 Mar 2022 | ₹4.99 Cr | Open |
How Many Employees Work at Axacus Pharma?
Axacus Pharma has a workforce of 7 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axacus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axacus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
